Literature DB >> 15212825

Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease.

Beatrice Arosio1, Daria Trabattoni, Lorenza Galimberti, Paolo Bucciarelli, Francesca Fasano, Carmen Calabresi, Carlo Lorenzo Cazzullo, Carlo Vergani, Giorgio Annoni, Mario Clerici.   

Abstract

In the pathogenesis of Alzheimer disease (AD), it has been proposed that the anti-inflammatory interleukins such as IL-10 regulate beta-amyloid-induced microglial inflammatory responses inhibiting the proinflammatory cytokine IL-6. Since the promoters of the IL-10 and IL-6 genes show single nucleotide polymorphisms (SNPs) (IL-10: -1082 G --> A; IL-6: -174 G --> C), we investigated these SNPs and cytokine production by peripheral blood mononuclear cells in 65 AD patients and 65 controls (HC). In AD there was a significant increase of the -1082A IL-10 allele (P=0.009) and a decrease of -1082GG genotype (P=0.019). The frequency of the GG IL-6 genotype in AD was lower and the C allele significantly higher (P <0.005). The co-occurrence of IL-10 A and IL-6 C alleles significantly raised the odds ratio (OR 11.2, confidence interval: CI 1.3-97.3; P <0.05) independently of apolipoprotein E4 (adjusted OR 10.3, CI 1-108; P <0.05). Only amyloid-stimulated IL-10 production differed between the groups (P=0.023). These results raise questions regarding the inflammatory theory in AD, pointing to a pivotal role of IL-10 and IL-6 and a selective alteration in this network.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15212825     DOI: 10.1016/j.neurobiolaging.2003.10.009

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  34 in total

1.  Interaction between interleukin-6 and intercellular adhesion molecule-1 genes and Alzheimer's disease risk.

Authors:  Onofre Combarros; Jon Infante; Javier Llorca; Nicolás Peña; Carlos Fernández-Viadero; José Berciano
Journal:  J Neurol       Date:  2005-03-22       Impact factor: 4.849

Review 2.  Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects.

Authors:  Agnes L F Chan; Yie W Chien; Shun Jin Lin
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 3.  Targeting innate immunity for neurodegenerative disorders of the central nervous system.

Authors:  Katrin I Andreasson; Adam D Bachstetter; Marco Colonna; Florent Ginhoux; Clive Holmes; Bruce Lamb; Gary Landreth; Daniel C Lee; Donovan Low; Marina A Lynch; Alon Monsonego; M Kerry O'Banion; Milos Pekny; Till Puschmann; Niva Russek-Blum; Leslie A Sandusky; Maj-Linda B Selenica; Kazuyuki Takata; Jessica Teeling; Terrence Town; Linda J Van Eldik
Journal:  J Neurochem       Date:  2016-09       Impact factor: 5.372

4.  Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease.

Authors:  Antonio L Teixeira; Breno S Diniz; Alline C Campos; Aline S Miranda; Natalia P Rocha; Leda L Talib; Wagner F Gattaz; Orestes V Forlenza
Journal:  Neuromolecular Med       Date:  2012-09-28       Impact factor: 3.843

Review 5.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

6.  IL-33 and its decoy sST2 in patients with Alzheimer's disease and mild cognitive impairment.

Authors:  Marina Saresella; Ivana Marventano; Federica Piancone; Francesca La Rosa; Daniela Galimberti; Chiara Fenoglio; Elio Scarpini; Mario Clerici
Journal:  J Neuroinflammation       Date:  2020-06-06       Impact factor: 8.322

Review 7.  Association between polymorphism in the promoter region of Interleukin 6 (-174 G/C) and risk of Alzheimer's disease: a meta-analysis.

Authors:  Limeng Dai; Dan Liu; Hong Guo; Yanyan Wang; Yun Bai
Journal:  J Neurol       Date:  2011-07-12       Impact factor: 4.849

8.  The changing microbial environment and chronic inflammatory disorders.

Authors:  Graham Aw Rook
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

9.  Intereleukin-10 promoter polymorphism in mild cognitive impairment and in its clinical evolution.

Authors:  Beatrice Arosio; Luigina Mastronardi; Carlo Vergani; Giorgio Annoni
Journal:  Int J Alzheimers Dis       Date:  2010-07-20

10.  Aromatase and interleukin-10 genetic variants interactively modulate Alzheimer's disease risk.

Authors:  O Combarros; P Sánchez-Juan; J A Riancho; I Mateo; E Rodríguez-Rodríguez; J Infante; I García-Gorostiaga; J L Vázquez-Higuera; J Berciano
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.